Axiom Biosciences

Axiom Biosciences is a San Diego-based clinical-stage biotechnology company developing regenerative therapies and targeted biologics for diseases with major unmet need. The company rebranded from Cytonus Therapeutics in June 2026 and is building on a foundation in regenerative cell therapy, particularly umbilical cord-derived mesenchymal stem cell programs for severe neonatal brain injury. Axiom has reported positive Phase 1 results for its lead investigational stem cell therapy in newborns with severe brain injury and has said it plans to expand the platform into adult ischemic stroke and other neurological indications. Beyond cell therapy, the company describes broader capabilities in AI-enabled drug design, targeted delivery, and translational science, including work related to localized mRNA therapeutic delivery. In July 2026, Axiom announced its intention to pursue an IPO on the Hong Kong Stock Exchange.